La Revue de médecine interne
-
Belimumab is currently approved for the treatment of active systemic lupus erythematosus (SLE). The aim of our study was to evaluate the efficacy of belimumab in the treatment of cutaneous lupus erythematosus (CLE), resistant to conventional therapy. ⋯ Our study suggests the clinical efficiency of belimumab in a series of 7 patients presenting a resistant and progressive CLE.